Henrietta Lacks HeLa Cell Line: Consent, Race, and Medical Research (1951)

Introduction

Henrietta Lacks was a 31-year-old Black tobacco farmer from Clover, Virginia, when she was diagnosed with cervical cancer at Johns Hopkins Hospital in Baltimore in January 1951. During her treatment, a tissue sample was taken from her tumour — without her knowledge or consent, though this was standard medical practice at the time. That sample became one of the most consequential biological specimens in the history of medicine.

The HeLa Cell Line

Researcher George Gey at Johns Hopkins cultured cells from Lacks''s biopsy and discovered they behaved unlike any human cells previously observed: they did not die. Normal human cells divide a limited number of times before dying; Lacks''s cancer cells divided indefinitely under laboratory conditions. Gey named the cell line ''HeLa'' (from Henrietta Lacks) and shared samples with researchers around the world at no charge.

The HeLa cell line was instrumental in Jonas Salk''s development of the polio vaccine in 1952. It has since been used in research on HPV and cervical cancer causation, in-vitro fertilization techniques, cancer biology, radiation effects, and — decades later — COVID-19 vaccine development. HeLa cells have been used in more than 70,000 published scientific studies.

The Family''s Exclusion

Henrietta Lacks died on 4 October 1951, eight months after her diagnosis. Her family was not informed that her cells had been cultured, distributed, and commercialized. They learned of the cell line''s existence only in 1973, when researchers studying the HeLa genome contacted family members for genetic comparison samples — again without adequate explanation of the implications.

Rebecca Skloot''s ''The Immortal Life of Henrietta Lacks'' (Crown, 2010) brought the case to mass public attention, describing both the scientific significance of HeLa cells and the Lacks family''s complete exclusion from the commercial and scientific benefits derived from Henrietta''s tissue. An HBO documentary adaptation, produced by Oprah Winfrey, was released in 2017.

Consent, Race, and Medical Ethics

The absence of informed consent was not anomalous in 1951 — patients routinely had tissue taken without specific consent for research use. But the case became a landmark in debates about informed consent, bodily autonomy, bioethics, and the intersection of race and medicine. The Lacks case is now taught in medical and bioethics curricula as a foundational example of how marginalized patients — particularly Black Americans — have historically borne the costs of medical advancement without sharing its benefits.

The racial dimension is inseparable from the case''s significance. Johns Hopkins served a largely Black patient population in a segregated Baltimore, and the tissue was taken from a patient who had no meaningful ability to negotiate the terms of her care.

Commercial Exploitation and Legal Resolution

HeLa cells became a commercial product. Biotech and pharmaceutical companies, including Thermo Fisher Scientific, commercialized HeLa-derived research tools. On 1 August 2023, the Lacks family reached a settlement with Thermo Fisher Scientific — the amount was not disclosed publicly, but the settlement was the first time a company had been held legally accountable for commercial use of HeLa cells. The case was brought by the family''s attorney and represented the first major legal resolution in over 70 years of commercial HeLa use.

Verdict

Confirmed. The non-consensual tissue collection, the cell line''s commercial and scientific use, the family''s exclusion, and the racial context are all thoroughly documented. The 2023 settlement acknowledges commercial exploitation in legal terms. The case represents a confirmed instance of a Black patient''s biological material being appropriated without consent or compensation for decades of profitable use.

What Further Research Should Examine

• Full scope of HeLa commercialization and whether other companies follow Thermo Fisher in reaching settlements
• Federal policy on compensation and consent for biospecimen research use
• Broader reckoning with historical non-consensual tissue collection from Black and incarcerated patients

The 2013 Genome Crisis: When HeLa's DNA Went Public Without Warning

The Lacks family's exclusion from decisions about Henrietta's cells did not end with her death in 1951 or even with Rebecca Skloot's 2010 book. It resurfaced sharply in March 2013, when researchers at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, published a full DNA sequence of the HeLa genome in the journal G3: Genes, Genomes, Genetics on 11 March 2013. The publication made the complete genetic blueprint of the cell line freely downloadable — and because HeLa cells are Henrietta Lacks's own cancerous cells, the sequence also revealed inheritable genetic information about her living descendants, including markers relevant to their own health risks. None of the family had been consulted or informed in advance.

Rebecca Skloot broke the story publicly in a New York Times opinion piece, and the backlash was immediate. At least 15 people had already downloaded the dataset before the EMBL team, facing criticism from bioethicists and the Lacks family alike, apologized and voluntarily withdrew the sequence from public access. The episode demonstrated that the ethical failure of 1951 was not a one-time historical event — sixty-two years later, scientists were still publishing sensitive information derived from Henrietta Lacks's body without asking her family's permission, even though modern genomic science made the privacy stakes far higher than anyone in 1951 could have anticipated.

The NIH-Lacks Family Agreement (August 2013)

The EMBL controversy forced the National Institutes of Health to act. NIH Director Francis Collins and Deputy Director Kathy Hudson travelled to Baltimore on three separate occasions to meet directly with Lacks family members, seeking a framework that would let biomedical researchers keep using HeLa genomic data while giving the family a genuine say in how it was governed. On 7 August 2013, NIH and the Lacks family jointly announced the result: the NIH-Lacks Family Agreement.

Under the agreement, any HeLa whole-genome sequence data generated with NIH funding must be deposited in the NIH's controlled-access Database of Genotypes and Phenotypes (dbGaP) rather than posted openly online. A six-person HeLa Genome Data Access Working Group — three scientists, one bioethicist, and two members of the Lacks family — reviews every application to use the data. Approved researchers must use the data only for biomedical research, disclose any commercial plans, acknowledge Henrietta Lacks and her family in resulting publications, and agree not to attempt to contact family members directly. It was the first time any federal agency had formally written a family's ongoing consent and oversight into the governance of a research resource derived from tissue taken without that same family's permission six decades earlier. NIH continues to update the technical terms of the agreement; a 2024 NIH guide notice reaffirmed the submission and access rules for HeLa whole-genome data under the same family-negotiated framework.

The Path to the 2021 Lawsuit

The NIH agreement addressed data governance, but it did not touch the far larger question of commercial profit. For seventy years, biotechnology and pharmaceutical companies had sold HeLa cells and HeLa-derived products — research reagents, engineered cell lines, testing kits — without ever compensating the Lacks estate. On 4 October 2021, exactly seventy years to the day after Henrietta Lacks's death, her estate filed suit against Thermo Fisher Scientific in the U.S. District Court for the District of Maryland. The estate was represented by civil rights attorney Ben Crump alongside Christopher Seeger of Seeger Weiss.

The complaint's central legal theory was unjust enrichment: it alleged that Thermo Fisher knowingly manufactured and sold products containing HeLa cells, generating substantial revenue, while never seeking consent from Lacks or compensating her descendants. The lawsuit asked the court to order Thermo Fisher to disgorge "the full amount of its net profits obtained by commercializing the HeLa cell line." Co-counsel Christopher Seeger signaled at the time that Thermo Fisher was only the opening target, telling reporters the company "shouldn't feel too alone because they're going to have a lot of company soon" — a warning that additional suits against other firms that commercialized HeLa products could follow.

Henrietta Lacks's grandson, Ron Lacks, spoke about the years of being sidelined by the same institutions that profited from his grandmother's cells: "When we went to the National Institutes of Health and Johns Hopkins, they totally ignored my father at the table with his lawyer." Crump framed the case in terms of legacy and equity, arguing that just as other American families have built generational wealth from a relative's contributions, the Lacks family deserved a share of the value created from Henrietta's genetic material.

The August 2023 Settlement

Thermo Fisher initially moved to dismiss the case, arguing the statute of limitations had expired given that the underlying conduct began in the 1950s. The motion was denied, and the case proceeded toward trial. On 1 August 2023 — deliberately timed to coincide with what would have been Henrietta Lacks's 103rd birthday — the parties announced they had reached a settlement. In a joint statement, Crump, Seeger, and Thermo Fisher confirmed that "members of the family of Henrietta Lacks and Thermo Fisher have agreed to settle the litigation filed by Henrietta Lacks' Estate, in U.S. District Court in Baltimore," adding that the terms would remain confidential and that neither side would comment further.

Bioethicists and legal scholars described the settlement as historically significant even without a public dollar figure attached. Law professor Deleso Alford, who supported the case, argued that the outcome helped restore Henrietta Lacks's identity and humanity to a scientific record that had for decades referred only to "HeLa" — a name deliberately chosen to obscure the real woman behind it. Coverage in Nature, Science, and STAT News agreed that while the settlement did not set binding legal precedent for other plaintiffs, it was the first instance of any company being held financially accountable, through a negotiated resolution, for profiting from HeLa cells — after roughly 75,000 published studies and an estimated tens of billions of dollars in aggregate industry revenue tied to products and research built on the cell line. The Lacks family's attorneys have indicated the Thermo Fisher case was intended as a template, not an endpoint, for pursuing other companies that commercialized HeLa-derived products.

Nuance and Limits: What the Case Does — and Does Not — Establish

A rigorous accounting of the Henrietta Lacks case requires acknowledging several limits on the claims of wrongdoing, alongside the confirmed core facts.

First, taking tissue without specific informed consent was standard, legal medical practice in the United States in 1951. There was no federal law requiring informed consent for research use of tissue removed during treatment; the modern informed-consent regime did not exist yet. The National Research Act of 1974 — passed in direct response to revelations about the Tuskegee syphilis study — created the National Commission for the Protection of Human Subjects, which in turn produced the 1979 Belmont Report and the eventual "Common Rule" governing human-subjects research. None of this existed in 1951. Johns Hopkins Medicine's own historical statement acknowledges that the collection and use of Henrietta Lacks's cells in research was, by the legal and ethical standards of the time, an accepted practice, even as it says the hospital "could have — and should have — done more to inform and work with members of Henrietta Lacks' family out of respect for them, their privacy and their personal interests."

Second, Johns Hopkins itself has never patented the HeLa cell line, and the university states it has never sold or profited from the discovery or distribution of HeLa cells; George Gey distributed samples to other researchers free of charge specifically to advance polio and cancer research. The profit that flowed from HeLa cells accrued overwhelmingly to third-party biotechnology and pharmaceutical companies — including Thermo Fisher — that later manufactured and sold HeLa-derived research products, not to Johns Hopkins as an institution. Johns Hopkins has, however, faced its own separate criticism for allegedly excluding family members from later discussions, and the university broke ground in October 2024 on a new building named in Henrietta Lacks's honor as part of its response.

Third, the scope of what the family is actually owed remains genuinely disputed, including within the family itself. Henrietta's oldest son, Lawrence Lacks, has separately argued that the 2013 NIH-Lacks Family Agreement is invalid because he was excluded from the negotiations that produced it, and he has pursued his own claims against Johns Hopkins directly — a dispute that remains unresolved and illustrates that "the family" has not spoken with one unified legal voice on every point. The Thermo Fisher settlement amount itself was never disclosed, so it is not possible to independently verify whether the compensation reflects a fair share of the value HeLa cells generated industry-wide, or a smaller negotiated figure reflecting litigation risk on both sides.

Fourth, a persistent myth around the case should be corrected: for years, some scientific literature and media reports referred to the cell donor using the pseudonym "Helen Lane" (or other invented names) rather than Henrietta Lacks's real identity — an additional layer of erasure that ran alongside, but is distinct from, the original consent violation. That misattribution has since been corrected in the scientific and popular record, in large part because of Skloot's reporting.

Congressional and Public Recognition

Beyond the legal settlement, Henrietta Lacks has received a wave of formal public recognition in the years since Skloot's book popularized her story. Members of Congress — including Representative Kweisi Mfume and Senators Chris Van Hollen and Ben Cardin, all of Maryland — introduced legislation to posthumously award Henrietta Lacks the Congressional Gold Medal, the highest civilian honor Congress can bestow, in recognition of her unwitting contribution to modern medicine. In her hometown of Roanoke, Virginia, city officials and the Roanoke Hidden Histories initiative raised more than $160,000 to commission a bronze statue of Lacks; the statue was placed in what is now called Henrietta Lacks Plaza — a downtown site that had previously held a Confederate statue of General Robert E. Lee, removed in 2020 amid nationwide protests. The statue design was unveiled in October 2023. These acts of memorialization run in parallel with the unresolved legal and financial questions: symbolic recognition has moved faster, and with less controversy, than compensation.

Why the Verdict Remains Confirmed

None of these nuances change the core, well-documented facts: tissue was taken from Henrietta Lacks without her knowledge or consent; the resulting HeLa cell line was distributed and eventually commercialized on a massive scale by companies other than Johns Hopkins; her family was kept in the dark for 22 years and then, even after learning the cells existed, was repeatedly excluded from decisions about their use — including as late as 2013, when a genome sequence with implications for their own genetic privacy was published without any of them being asked. The 2023 Thermo Fisher settlement is the first instance of legal accountability for commercial HeLa profit, and it followed a direct, well-documented chain of evidence from the original 1951 biopsy through seventy years of use. The debate that remains live is not whether these events happened, but how much is owed, to whom, and by which of the many companies that built products on Henrietta Lacks's cells — questions the Thermo Fisher settlement opened rather than closed.